Safety across the full program was consistently favorable: adverse events, primarily mild headache and gastrointestinal symptoms, occurred at rates comparable to placebo, with no treatment-related discontinuations, no IGF-1 elevation, and no impact on glucose metabolism
It could also reduce markers of liver inflammatory activities and support reduction in body weight, fat mass, and hip circumference, all while being safe and well-tolerated
Being overweight, having psychiatric disorders, having asthma, and being in poor general health are risk factors
For those with diabetes or significant glucose variability, CGMs offer valuable insights
Wegovy 1.7mg FlexTouch solution for injection in pre-filled pen Manufacturer: Novo Nordisk India Pvt Ltd Wegovy 1.7mg FlexTouch is a medicine that aids in weight loss and maintenance for overweight or obese adults
Understanding the precise mechanism by which GLP-1 agonists work is essential when evaluating whether other compounds, such as berberine, share similar pharmacological properties
